Advancing access to cell and gene therapies through the Advanced Therapeutics Alliance

Advanced therapeutics are expanding treatment possibilities for patients while creating new operational, financial and access challenges for health systems. Host Carolyn Liptak joins Elizabeth Oyekan, Lynn Eschenbacher and Carina Dolan to discuss the Advanced Therapeutics Alliance, a provider-led collaborative that brings together healthcare providers, payers, pharmaceutical companies and other industry partners to improve access to cell and gene therapies through shared knowledge, coordinated action and cross-sector collaboration.  To join the alliance, visit Advanced Therapeutics Alliance (https://campaigns.vizientinc.com/ther...) .    Guest Speakers:  Elizabeth Oyekan, PharmD, FCSHP, CPHQ, CPEL  President  FiveTwo Health Partners    Lynn Eschenbacher, PharmD, MBA, FASHP, CPEL  Chief Pharmacy Officer and Strategy Officer  PharmaForce     Carina Dolan, PharmD, MS Pharm, BCOP  AVP, Market Insights & Forecasting  Vizient Clinical Spend Management    Host:  Carolyn Liptak, MBA, BS Pharm  Pharmacy Executive Director, Regulatory Compliance  Vizient Center for Pharmacy Practice Excellence     Show Notes:  [01:07]  • How fragmented systems can create delays for patients  • The development of the Advanced Therapeutics Alliance and its focus on access, sustainability, and equity  [02:40]  • The challenges created by single case agreements, payer requirements, and manual processes • The value of health systems sharing solutions instead of addressing similar challenges independently  [04:14]  • Common concerns across health systems related to reimbursement, infrastructure, patient access, payer variability, and long term sustainability  • The importance of connecting organizations that are facing similar challenges  •  Why improving access to advanced therapies requires collaboration across the healthcare ecosystem  [06:06]  • Pharmacy’s role across clinical care, operations, finance, regulatory requirements, and patient support  • The importance of involving pharmacy leaders early in the development   • Opportunity for pharmacy to help lead this work while bringing the right partners to the table  [08:48]  • The need for collaboration among pharmacy, physicians, nursing, finance, revenue cycle, administration, manufacturers, payers, and patient advocacy organizations  • How pharmacy leaders are helping their organizations establish the policies, resources, and processes needed to support advanced therapies  • The Alliance’s role in extending collaboration beyond individual health systems  [10:33]  • What distinguishes the Advanced Therapeutics Alliance from other efforts in this space  •  The focus on turning shared experiences into practical action  [11:23]  •  How greater understanding across the healthcare ecosystem can support scalable and sustainable processes • The role of Vizient in connecting providers, manufacturers, payers, and other partners  [12:26]  • How organizations can bring forward their priorities, experiences, challenges, and ideas • The goal of translating existing knowledge into action that can be shared across organizations  [13:05]  • The Alliance’s mission to increase patient access to life changing therapies  • The need to build sustainable processes that can support the growing number of advanced therapies  [14:48]  • The value of joining the Alliance while its work groups and resources are being established  • How pharmacy leaders can learn from peers and bring new perspectives back to their organizations  [16:32]  • The importance of sharing real world experiences and contributing to collaborative solutions  • The call for stakeholders across the cell and gene therapy ecosystem to help improve access and sustainability for patients    Links and Resources: • Advanced Therapeutics Alliance (https://campaigns.vizientinc.com/ther...) • Vizient Cell & Gene Therapy (https://www.vizient.com/products/phar...) • Advancing cell, gene, and specialty therapies requires enterprise transformation (https://www.vizient.com/insights/arti....